# HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM

> **NCT04547621** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Huashan Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Glioma, Malignant

## Interventions

- **DEVICE:** Radiation
- **DEVICE:** Radiation
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04547621
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547621, "HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04547621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*